Literature DB >> 24600488

Serine threonine kinase Pim-3 regulates STAT3 pathway to inhibit proliferation of human liver cancers.

Jianqiang Wang1, Lijun Lao2, Hui Zhao1, Yuan Huang1.   

Abstract

OBJECTIVE: This study aimed to investigate the effects of serine threonine kinase Pim-3 on the growth of HepG2 cells and to explore the role of STAT3 signaling pathway.
METHODS: Synthetic Pim-3shRNA and negative control shRNA were independently transfected into HepG2 cells in the presence of Lipofectamine(TM) 2000. Cells were divided into 4 groups: Pim-3 shRNA group, negative control group, liposome control group, and blank control group. Flow cytometry was performed to detect the apoptosis of these cells; RT-PCR was employed to detect the mRNA expression of Pim-3; Western blot assay was done to measure the protein expression of Pim-3, STAT3, pSTAT3(Tyr705), Bcl-Xl, Bad and pBad(Ser112).
RESULTS: When compared with blank control group, liposome group and negative control group, the apoptosis index increased and the protein expression of Pim-3, pSTAT3(Tyr705), Bcl-Xl and pBad(Ser112) and the Pim-3 mRNA expression reduced in the Pim-3 shRNA group, but the protein expression of STAT3 and Bad was comparable among groups.
CONCLUSION: Pim-3 shRNA may down-regulate pSTAT3(Tyr705) and pBad(Ser112) protein expression to inhibit the proliferation of liver cancer cells and Pim-3 may serve as a target for the treatment of liver cancer.

Entities:  

Keywords:  STAT3; Serine threonine kinase Pim-3; apoptosis; liver tumor

Year:  2014        PMID: 24600488      PMCID: PMC3931587     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  40 in total

Review 1.  Hepatocellular carcinoma--epidemiological trends and risk factors.

Authors:  Kerstin Schütte; Jan Bornschein; Peter Malfertheiner
Journal:  Dig Dis       Date:  2009-06-22       Impact factor: 2.404

Review 2.  New and old functions of STAT3: a pivotal target for individualized treatment of cancer.

Authors:  Giorgio Inghirami; Roberto Chiarle; William J Simmons; Roberto Piva; Karni Schlessinger; David E Levy
Journal:  Cell Cycle       Date:  2005-09-30       Impact factor: 4.534

Review 3.  Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.

Authors:  Masatoshi Kudo
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

Review 4.  Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.

Authors:  Zhigang Wang; Guofeng Zhang; Jiacheng Wu; Mingku Jia
Journal:  Drug Discov Ther       Date:  2013-08

5.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.

Authors:  Guilian Niu; Kenneth L Wright; Mei Huang; Lanxi Song; Eric Haura; James Turkson; Shumin Zhang; Tianhong Wang; Dominic Sinibaldi; Domenico Coppola; Richard Heller; Lee M Ellis; James Karras; Jacqueline Bromberg; Drew Pardoll; Richard Jove; Hua Yu
Journal:  Oncogene       Date:  2002-03-27       Impact factor: 9.867

6.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.

Authors:  Daoyan Wei; Xiangdong Le; Leizhen Zheng; Liwei Wang; Jennifer A Frey; Allen C Gao; Zhihai Peng; Suyun Huang; Henry Q Xiong; James L Abbruzzese; Keping Xie
Journal:  Oncogene       Date:  2003-01-23       Impact factor: 9.867

Review 7.  Canonical and non-canonical JAK-STAT signaling.

Authors:  Willis X Li
Journal:  Trends Cell Biol       Date:  2008-10-09       Impact factor: 20.808

8.  Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.

Authors:  E Yang; J Zha; J Jockel; L H Boise; C B Thompson; S J Korsmeyer
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

9.  Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines.

Authors:  Chifumi Fujii; Yasunari Nakamoto; Peirong Lu; Koichi Tsuneyama; Boryana K Popivanova; Shuichi Kaneko; Naofumi Mukaida
Journal:  Int J Cancer       Date:  2005-03-20       Impact factor: 7.396

10.  Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas.

Authors:  G Selten; H T Cuypers; A Berns
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

View more
  1 in total

1.  Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients.

Authors:  Rong-Xin Zhang; Zhong-Guo Zhou; Shi-Xun Lu; Zhen-Hai Lu; De-Sen Wan; Zhi-Zhong Pan; Xiao-Jun Wu; Gong Chen
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.